Rubratin

Drug Profile

Rubratin

Alternative Names: N CWS; Nocardia CWS; Rubratine

Latest Information Update: 23 Jun 1998

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Fujisawa
  • Developer ASTA Medica [CEASED]; Fujisawa
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 23 Jun 1998 Commercial data has been reviewed by Fujisawa
  • 30 May 1995 Discontinued-preregistration for Cancer in Japan (Unknown route)
  • 30 May 1995 Discontinued-Unspecified phase in Cancer in Germany (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top